Mark Wilterding
Known title: Chief Financial OfficerCIK: 0002107187
Associated companies
Transaction History
| RXST | ▼ Sell | Open Market | 7,765 | $54K | 9/2/2026 | View on chart |
| RXST | ▲ Buy | Option Exercise | 20,441 | — | 8/31/2026 | View on chart |
| RXST | ▲ Buy | Option Exercise | 20,441 | — | 2/28/2026 | View on chart |
| RXST | ▼ Sell | Tax Withholding | 8,068 | $61K | 2/28/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.